Tesamorelin
Fat LossFDA-approved GHRH analogEstablished
FDA-approved GHRH analog (Egrifta) to reduce excess visceral abdominal fat in HIV-associated lipodystrophy. WADA still prohibits tesamorelin (S2) in sport.
For research use only.
Key Facts
- CAS
- 218949-48-5
- Molecular Weight (MW)
- 5135.9 g/mol
- Half-life
- 26-38 minutes
- Unit
- mg
- Administration Route
- Subcutaneous
- Frequency
- Daily
- Last updated
- 8/23/2026
- Targets
- GHRH receptor
Overview
FDA-approved GHRH analog (Egrifta) to reduce excess visceral abdominal fat in HIV-associated lipodystrophy. WADA still prohibits tesamorelin (S2) in sport.
Protocol
- Dosage Range
- 1-2 mg
- Frequency
- Daily
- Cycle
- 12-16 weeks on, 4 off
- Administration Route
- Subcutaneous
- Reconstitution Guide
- 3 mL BAC for 10 mg vial
Science
Mechanism of Action
Stabilized GHRH analog that increases endogenous GH/IGF-1 and preferentially reduces visceral adipose tissue in the labeled HIV population.
Targets
GHRH receptor
Studies
- Tesamorelin VAT reduction— Journal/year not available
Benefits
Labeled HIV lipodystrophy VAT reduction
Potential Side Effects
- Arthralgia
- Edema
- Hyperglycemia
- Injection reactions
References
- FDA label — Egrifta WRExternal link · Year —
- WADA Prohibited List 2026External link · Year —